The charts on this page feature a breakdown of the total annual pay for the top executives at ACORDA THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ACORDA THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ACORDA THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Ron Cohen M.D.
President and Chief Executive Officer
Total Cash $2,406,121 Equity $0 Other $8,250 Total Compensation $2,414,371
Andrew Hindman
Chief Business Officer
Total Cash $1,145,747 Equity $0 Other $8,250 Total Compensation $1,153,997
Burkhard Blank M.D.
Chief Medical Officer and Head of R&D
Total Cash $1,276,534 Equity $0 Other $63,602 Total Compensation $1,340,136
David Lawrence
Chief, Business Operations and Principal Accounting Officer
Total Cash $964,350 Equity $0 Other $8,250 Total Compensation $972,600
Jane Wasman
President, International, General Counsel and Corporate Secretary
Total Cash $1,434,443 Equity $0 Other $8,250 Total Compensation $1,442,693
For its 2018 fiscal year, ACORDA THERAPEUTICS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Ron Cohen M.D. CEO Pay $2,414,371 Median Employee Pay $202,725 CEO Pay Ratio 12:1
For its 2018 fiscal year, ACORDA THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Barry Greene Total Cash $292,369
Catherine Strader Total Cash $348,470
Ian Smith Total Cash $296,369
John P. Kelley Total Cash $297,369
Lorin J. Randall Total Cash $290,369
Peder K. Jensen, M.D Total Cash $296,369
Sandra Panem, Ph.D. Total Cash $294,369
Steven M. Rauscher Total Cash $292,369

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.